• Explore /
  • Poster
  • / SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.

SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.

Abstract Poster

Authors

Amita Patnaik

Amita Patnaik

START, San Antonio, TX

Amita Patnaik , Funda Meric-Bernstam , Caio Max Sao Pedro Rocha Lima , Francisco Robert , Afshin Dowlati , Hedy L. Kindler , Diwakar Davar , Steven Francis Powell , Phillip M. Garfin , Ani Sarkis Balmanoukian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT04042480

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS3652)

DOI

10.1200/JCO.2020.38.15_suppl.TPS3652

Abstract #

TPS3652

Poster Bd #

382

Abstract Disclosures

Similar Posters

First Author: Funda Meric-Bernstam

First Author: Vivek Subbiah

First Author: Angela Tatiana Alistar

First Author: Breelyn A. Wilky